Table 1 Treatment effects within subgroups defined by primary tumor location in patients with RAS wild-type metastatic colorectal cancer

 PRIME [20]

FOLFOX + panitumumab

FOLFOX

16

16

38

46

42.1

34.8

1.364

0.56–3.30

0.492

 TAILOR [21]

FOLFOX + cetuximab

FOLFOX

20

9

45

38

44.4

23.7

2.578

0.99–6.67

0.051

 CRYSTAL [22]

FOLFIRI + cetuximab

FOLFIRI

1417

3351

42.4

33.3

1.474

0.60–3.64

0.4

 MACRO-2/PLANET [25]

FOLFIRI/FOLFOX + panitumumab

11

33

33.3

–

–

–

 VOLFI [23]

FOLFOXIRI + panitumumab

FOLFOXIRI

6

3

10

8

60

37.5

2.500

0.37–16.88

0.347

 PEAK [20]

FOLFOX + panitumumab

FOLFOX + bevacizumab

14

7

22

14

63.6

50.0

1.75

0.45–6.83

0.42

 FIRE-3 [24]

FOLFIRI + cetuximab

FOLFIRI + bevacizumab

18

19

30

38

60.0

50.0

1.500

0.57–3.95

0.412

 CALGB80405 [13]

FOLFIRI/FOLFOX + cetuximab

FOLFIRI/FOLFOX + bevacizumb

30

31

71

78

42.3

39.7

1.109

0.58–2.13

0.756

 PRIME [20]

FOLFOX + panitumumab

FOLFOX

114

82

168

156

67.9

52.6

1.905

1.21–2.99

0.005

 TAILOR [21]

FOLFOX + cetuximab

FOLFOX

97

70

146

162

66.4

43.2

2.602

1.63–4.13

< 0.001

 CRYSTAL [22]

FOLFIRI + cetuximab

FOLFIRI

103

56

142

138

72.5

40.6

3.867

2.34–6.38

< 0.001

 MACRO-2/PLANET [25]

FOLFIRI/FOLFOX + panitumumab

78

148

52.7

–

–

–

 VOLFI [23]

FOLFOXIRI + panitumumab

FOLFOXIRI

48

17

53

25

90.6

68

4.518

1.30–15.72

0.018

 PEAK [20]

FOLFOX + panitumumab

FOLFOX + bevacizumab

34

31

53

54

64.1

57.4

1.328

0.61–2.89

0.476

 FIRE-3 [24]

FOLFIRI + cetuximab

FOLFIRI + bevacizumab

93

78

124

133

75.0

58.6

2.115

1.24–3.60

0.006

 CALGB80405 [13]

FOLFIRI/FOLFOX + cetuximab

FOLFIRI/FOLFOX + bevacizumb

120

88

173

152

69.4

57.9

1.647

1.04–2.60

0.032